Schubert et al.35investigated the relationships among the molecular properties, ocular pharmacokinetics, and pharmacology of the anti-VEGF agents aflibercept, brolucizumab, and ranibizumab to characterize their efficacy in a preclinical rabbit model of retinopathy. This evidence concerns the gene VEGFA and retinal disorder.